You are not currently logged in.

Access JSTOR through your library or other institution:


Log in through your institution.

Journal Article

Automated Surveillance of Clostridium difficile Infections Using BioSense

Stephen R. Benoit , MD, MPH, L. Clifford McDonald , MD, Roseanne English , BS and Jerome I. Tokars , MD, MPH
Infection Control and Hospital Epidemiology
Vol. 32, No. 1 (January 2011), pp. 26-33
DOI: 10.1086/657633
Stable URL:
Page Count: 8
  • Subscribe ($19.50)
  • Add to My Lists
  • Cite this Item
Automated Surveillance of Clostridium difficile Infections Using BioSense
Preview not available


Objective.  To determine the feasibility of using electronic laboratory and admission‐discharge‐transfer data from BioSense, a national automated surveillance system, to apply new modified Clostridium difficile infection (CDI) surveillance definitions and calculate overall and facility‐specific rates of disease. Design.  Retrospective, multicenter cohort study. Setting.  Thirty‐four hospitals sending inpatient, emergency department, and/or outpatient data to BioSense. Methods.  Laboratory codes and text‐parsing methods were used to extract C. difficile–positive toxin assay results from laboratory data sent to BioSense during the period from January 1, 2007, through June 30, 2008; these were merged with administrative records to determine whether cases were community associated or healthcare onset, as well as patient‐day data for rate calculations. A patient was classified as having hospital‐onset CDI if he or she had a C. difficile toxin–positive result on a stool sample collected 3 or more days after admission and community‐onset CDI if the specimen was collected less than 3 days after admission or the patient was not hospitalized. Results.  A total of 4,585 patients from 34 hospitals in 12 states had C. difficile–positive assay results. More than half (53.0%) of the cases were community‐onset, and 30.8% of these occurred in patients who were recently hospitalized. The overall rate of healthcare‐onset CDI was 7.8 cases per 10,000 patient‐days, with a range among facilities of 1.5–27.8 cases per 10,000 patient‐days. Conclusions.  Electronic laboratory data sent to the BioSense surveillance system were successfully used to produce disease rates of CDI comparable to those of other studies, which shows the feasibility of using electronic laboratory data to track a disease of public health importance.

Page Thumbnails

Part of Sustainability